GlassScriptPhysician profile
Denise O'Riordan
NPI 1265709737
$2,104.02
in general payments reported to CMS, 2019-2025
48 companies · $390 in 2025
The $390 reported for 2025 was more than what 90% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $87.20 · 2021: $334 · 2022: $322 · 2023: $302 · 2024: $443 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,135.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $364.29 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $237.78 | 2019-2023 | Jornay Pm |
| Glaxosmithkline, LLC. | $172.77 | 2022-2025 | Bexsero, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $117.39 | 2021-2025 | Capvaxive, Gardasil 9, Enflonsia |
| Sanofi Pasteur INC. | $65.72 | 2021-2024 | |
| Ibsa Pharma INC. | $52.61 | 2021-2022 | |
| Agios Pharmaceuticals, INC. | $50.69 | 2024-2025 | Pyrukynd |
| Aimmune Therapeutics, INC. | $50.21 | 2025 | Zenpep |
| Novo Nordisk INC | $49.84 | 2019-2023 | Saxenda |
| Genzyme Corporation | $39.08 | 2023 | |
| Vanda Pharmaceuticals INC. | $35.01 | 2025 | Fanapt |
| Endo Pharmaceuticals INC. | $34.26 | 2019 | |
| Amgen INC. | $34.24 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $32.61 | 2021-2024 | Rexulti |
| Bausch Health US, LLC | $32.07 | 2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise O'Riordan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.